Clinical Research & Proven Results

At Hairmax®, we care, and that is why our 7 clinical studies were conducted at prestigious research universities throughout the U.S., including the Cleveland Clinic, the University of Miami and the University of Minnesota, applying the highest standards in the industry.

More Clinical Results than Any Other Laser Hair Growth Device


90% success rate, 129 additional new hairs per in. sq., 8 FDA Clearances & 6 published peer reviewed articles

Six of these studies were designed as multi-centered, double-blind and randomized control device.

Designed to provide support of 510(k) submissions to the FDA – Major factor in granting of Clearances.

Approved by an IRB (Independent Review Board)Complied with GCP (Good Clinical Practices) guidelines.

Monitored by a CRO (Contract Research Organization).

Monotherapy in a 54-year old male
a. Before Treatment | b. Improvement after 6 months | c. 12 months of low-level laser therapy

Filling in of hairline. Substantial increase in hair density. Overall improvement of hair quality. (After 26 weeks)

Filling in of hairline. Substantial increase in hair density. Overall improvement of hair quality. (After 26 weeks)

(Individual results may vary. Photos on this page may not represent typical results you can experience)


Clinical Study Non-Vellus Hair Density Macro Images

At baseline, a circle approximately 1 inch in diameter, positioned in the transition zone of the scalp, was identified as the site for hair clipping and tattooing. Within this site was the target area for the hair density evaluation during the laser hair growth treatment. Subjects were evaluated at baseline, week 8, week 16 and week 26. Digital images captured by FUJI S2 were taken of the target site within the clipped area following the site preparation. A 19 inch monitor was used for blinded evaluation.

Clinical Studies

The clinical studies included males & females between the ages of 25-60 yrs. with a diagnosis of Androgenetic Alopecia who had been experiencing active hair loss within the last 12 months. The inclusion criteria for males required a Norwood- Hamilton classification of IIa to V and Fitzpatrick skin types I to IV. Click for Classification Charts. The inclusion criteria for females required a Ludwig (Savin) classification of I-4, II-1, II-2, or frontal.
All subjects were randomized for laser hair loss treatment analysis. A biostatistician calculated the study to be of a proper size to gauge statistically significant results of hair growth and hair density. Subjects were instructed to use the laser hair growth treatment device three times per week on non-consecutive days, 10-15 minutes per treatment for a total of 26 weeks. Hair density measurements were performed at baseline, at 16 and 26 weeks. Additional clinical visits were scheduled to monitor the laser hair loss treatment progress and overall hair growth.
Below are the benefits participants experienced in clinical studies using Hairmax® Laser Devices after 26 weeks of use. (Ongoing treatment is required to maintain these benefits.)

  • Significant hair growth.
  • Reversal of the thinning process.
  • Increased density and fullness.
  • Avg. hair count increase: 129 hairs / sq. in.
  • A substantial decrease in hair fallout.
  • Increased rate of hair growth.
  • More manageability of the hair.
  • Overall better hair quality and condition.

Mean Terminal Hair Count Changes From Baseline in Males 26 Weeks, Last Observation Carried Forward.

Mean Terminal Hair Count Changes From Baseline in Females 26 Weeks, Last Observation Carried Forward.

Published Articles

2014 – Results of 4 clinical studies in males and females

Published in April 2014 in the peer review medical journal, The American Journal of Clinical Dermatology. 

Key Conclusions

  • Statistically significant increase in terminal hair density (thickness)
  • Higher percentage of LaserComb treated subjects reported overall improvement of hair loss condition and thickness and fullness of hair
  • Increase in hair counts was comparable to short-term clinical trials of 5% minoxidil (Rogaine) and 1mg/day finasteride (Propecia)
  • No serious side effects


2014 – Results of a retrospective study to evaluate efficacy and safety as mono or concomitant therapy

Published in April 2014 in the peer review journal, the International Journal of Trichology.

Key Conclusions

  • 88% of patients showed significant improvement when LaserComb added to drug treatment
  • 100% of all patients treated with the LaserComb after discontinuation of drug treatment showed significant improvement
  • Improvement was observed as early as 3 months
  • Efficacy sustained up to maximum observation time of 24 months
  • No adverse reactions reported


2003 – Results of hair regrowth and increased tensile strength

Published in November 2003 in the peer review journal, International Journal of Cosmetic Surgery and Aesthetic Dermatology

Key Conclusions

  • LaserComb stimulated hair growth
  • Increased tensile strength of hair in men and women
  • Effective in both vertex and temporal areas


What are you looking for?

Your cart